Skip Navigation

JNCI Journal of the National Cancer Institute 1989 81(23):1820-1823; doi:10.1093/jnci/81.23.1820
© 1989 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Abou-Issa, H.
Right arrow Articles by Moeschberger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abou-Issa, H.
Right arrow Articles by Moeschberger, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 81, No. 23, 1820-1823, December 6, 1989
© 1989 Oxford University Press

Chemotherapeutic Evaluation of Glucarate and N-(4-Hydroxyphenyl)retinamide Alone and in Combination in the Rat Mammary Tumor Model

Hussein Abou-Issa*,, Thomas E. Webb, John P. Minton, Melvin Moeschberger

Department of Surgery Columbus, OH
Department of Physiological Chemistry Columbus, OH
Department of Preventive Medicine and Biometrics Laboratory Ohio State University Columbus, OH

*Correspondence to:: Dr. Hussein Abou-Issa, Department of Surgery, Ohio State University, College of Medicine, 410 W. 10th Ave., Columbus, OH 43210.

We evaluated calcium glucarate (CGT) and N-(4-hydroxyphenyl)retinamide (HPR) for their effectiveness as antitumor agents. For this evaluation, we tested the effects of CGT and HPR given alone or combined in the diet on the growth of established 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors. When given alone, optimal doses of CGT (128.0 mmol/kg in the diet) or HPR (2.0 mmol/kg in the diet) administered daily for 25 days reduced mammary tumor sizes by approximately 15% or 20%, respectively. Suboptimal doses of CGT (64.0 mmol/kg) or HPR (0.75 mmol/kg) administered daily for 25 days only slightly inhibited tumor growth; over the 25-day period, the tumor sizes in rats on the CGT diet and in rats on the HPR diet increased by 55% and 70%, respectively, compared with a 98% increase in tumor sizes in the rats on the control diet. In contrast, the combination of suboptimal doses of CGT (64.0 mmol/kg) and HPR (0.75 mmol/kg) administered daily for 25 days decreased tumor sizes by 33%. These results are statistically significant. They show that CGT and HPR act synergistically. Consequently, lower concentrations of these agents can be used to inhibit mammary tumor development and growth. [J Natl Cancer Inst 81:1820–1823, 1989]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Tamagawa, K. Shimizu, T. Ebine, Y. Maitani, T. Fukui, K.-i. Kawai, and N. Takahashi
Antitumor Efficacy in Vitro and in Vivo of Falconensones, a New Type of Polyene
Clin. Cancer Res., November 1, 2001; 7(11): 3551 - 3558.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. E. Harris, G. A. Alshafie, H. Abou-Issa, and K. Seibert
Chemoprevention of Breast Cancer in Rats by Celecoxib, a Cyclooxygenase 2 Inhibitor
Cancer Res., April 1, 2000; 60(8): 2101 - 2103.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.